Literature DB >> 7916561

Toxicity of beta-blockers in a rat whole embryo culture: concentration-response relationships and tissue concentrations.

S Klug1, R Thiel, R Schwabe, H J Merker, D Neubert.   

Abstract

Beta-adrenoceptor blockers are widely used drugs for the treatment of cardiovascular diseases. Since beta-blockers cross the placenta, it is essential to consider possible adverse effects on the embryo. Six beta-adrenoceptor blockers were tested at various concentrations (10-5000 microM) in a rat whole embryo culture. Although inducing a very similar pattern of dysmorphogenetic effects (incomplete flexure, disturbed development of the neural tube, the head, the heart and the tail bud), the compounds exhibited a wide range of embryotoxic potency. Estimation of the EC50 (median-concentration producing dysmorphogenesis in 50% of the embryos) for the six compounds revealed differences of more than two orders of magnitude: propranolol 25 microM, alprenolol 30 microM, metoprolol 100 microM, pindolol 150 microM, acebutolol 500 microM, atenolol 4000 microM. Measurements of the concentrations of the various drugs in the cultured embryos at corresponding EC50 levels showed differing values: metoprolol 4.5 microM, propranolol 5.2 microM, alprenolol 8.4 microM, pindolol 9.0 microM, acebutolol 12.5 microM and atenolol 77.0 microM. With regard to the EC50 and the degree of substance transfer to the embryo it can be stated that propranolol and metoprolol show a much higher intrinsic potency to interfere with normal in vitro embryonic development than, e.g. atenolol.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7916561     DOI: 10.1007/s002040050085

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  28 in total

1.  Propranolol therapy during pregnancy, labor, and delivery: evidence for transplacental drug transfer and impaired neonatal drug disposition.

Authors:  C M Cottrill; R G McAllister; L Gettes; J A Noonan
Journal:  J Pediatr       Date:  1977-11       Impact factor: 4.406

2.  Status report on beta-blockers.

Authors: 
Journal:  FDA Drug Bull       Date:  1978 Mar-Apr

3.  Transdermal delivery of mepindolol and propranolol in normal man. 1st communication: study design, clinical and pharmacodynamic aspects.

Authors:  C de Mey; D Enterling; M Ederhof; H Wesche; H Osterwald
Journal:  Arzneimittelforschung       Date:  1989-11

Review 4.  Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 2. Physiologic and metabolic effects.

Authors:  W Frishman; R Silverman
Journal:  Am Heart J       Date:  1979-06       Impact factor: 4.749

Review 5.  The application of clearance concepts to propranolol disposition in man.

Authors:  G R Wilkinson
Journal:  Drug Metab Rev       Date:  1979       Impact factor: 4.518

Review 6.  A toxicological review of beta-adrenergic blockers.

Authors:  C D Jackson; L Fishbein
Journal:  Fundam Appl Toxicol       Date:  1986-04

7.  Measurement of hydrophobicity, surface activity, local anaesthesia, and myocardial conduction velocity as quantitative parameters of the non-specific membrane affinity of nine -adrenergic blocking agents.

Authors:  D Hellenbrecht; B Lemmer; G Wiethold; H Grobecker
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1973       Impact factor: 3.000

8.  Transplacental passage of atenolol in man.

Authors:  A Melander; B Niklasson; I Ingemarsson; H Liedholm; B Scherstén; N O Sjöberg
Journal:  Eur J Clin Pharmacol       Date:  1978-11-16       Impact factor: 2.953

9.  Propranolol, a phosphatidate phosphohydrolase inhibitor, also inhibits protein kinase C.

Authors:  S Sozzani; D E Agwu; C E McCall; J T O'Flaherty; J D Schmitt; J D Kent; L C McPhail
Journal:  J Biol Chem       Date:  1992-10-05       Impact factor: 5.157

10.  The role of pinocytosis in the cellular uptake of an amino acid.

Authors:  J G Thoene; S Forster; J B Lloyd
Journal:  Biochem Biophys Res Commun       Date:  1985-03-29       Impact factor: 3.575

View more
  1 in total

1.  Targeted disruption of the mouse beta1-adrenergic receptor gene: developmental and cardiovascular effects.

Authors:  D K Rohrer; K H Desai; J R Jasper; M E Stevens; D P Regula; G S Barsh; D Bernstein; B K Kobilka
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.